Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics Inc (TARA) is a clinical-stage biotechnology company developing transformative therapies for cancer and rare diseases. This page provides investors and industry observers with timely updates on clinical trials, regulatory milestones, and corporate developments.
Access comprehensive coverage of TARA's investigational cell therapy TARA-002 for lymphatic malformations and IV Choline Chloride research. Our news collection features press releases, peer-reviewed data publications, and strategic partnership announcements.
Key updates include progress reports on:
• Clinical trial phases
• FDA designations
• Scientific conference presentations
• Intellectual property developments
Bookmark this page for centralized access to Protara's latest advancements in immunopotentiator therapies and metabolic replacement solutions. Monitor critical updates affecting the company's position in the oncology and rare disease treatment landscapes.
Protara Therapeutics (TARA) announced significant updates regarding its clinical programs and financial results for the year ending December 31, 2022. Key highlights include expected data from the Phase 1a ADVANCED-1 trial for TARA-002 in treating non-muscle invasive bladder cancer (NMIBC) in 2Q23, and the initiation of Phase 2 trial activities for TARA-002 in lymphatic malformations (LMs) in 2H23. As of December 31, 2022, the company reported cash and equivalents of $102.3 million, anticipated to fund operations through 2025. However, TARA reported a net loss of $39 million for Q4, partly due to a $29.5 million goodwill impairment charge.
FAQ
What is the current stock price of Protara Therapeutics (TARA)?
What is the market cap of Protara Therapeutics (TARA)?
